Literature DB >> 12488272

Pericyte recruitment in human corneal angiogenesis: an ultrastructural study with clinicopathological correlation.

C Cursiefen1, C Hofmann-Rummelt, M Küchle, U Schlötzer-Schrehardt.   

Abstract

BACKGROUND/AIM: During angiogenesis-that is, the outgrowth of new from pre-existing blood vessels, new capillaries undergo a period of "fine tuning" when vascular endothelial cells become apoptotic if sufficient supply of angiogenic factors is lacking. Morphologically, this period correlates with the absence of pericyte coverage of new vessels. Mature, pericyte covered vessels, in contrast, do not depend on elevated levels of angiogenic factors for survival. This study analyses whether, and if so when, pathological vessels in human corneal neovascularisation (CN) acquire pericyte coverage. This can be of importance for future angioregressive therapeutic strategies.
METHODS: Vascularised human corneas obtained by keratoplasty were evaluated by electron microscopy for pericyte coverage of new vessels. These data were correlated with the duration of CN (mean 73 (SD 95) (range 0.5-360) months; n = 15). CN was secondary to keratitis, transplant rejection, aniridia, or trauma.
RESULTS: Overall, 196 blood vessels were analysed ultrastructurally (72 (37%) capillaries, 122 (62%) venules, and two (1%) arterioles). Electron microscopically, 170 (87%) vessels were covered by pericytes and two (1%) in addition by smooth muscle cells. Pericyte recruitment increased with time, evolving between clinically noted onset of CN and keratoplasty. Already 2 weeks after onset of CN, more than 80% of new vessels were covered by pericytes.
CONCLUSION: Pathological new vessels in human corneal angiogenesis are rapidly covered by pericytes. Therapeutic strategies aimed at regression of immature, not yet pericyte covered vessels by antagonising angiogenic factors should thus be most effective if applied very early in the course of corneal neovascularisation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12488272      PMCID: PMC1771468          DOI: 10.1136/bjo.87.1.101

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  28 in total

Review 1.  Vascular-specific growth factors and blood vessel formation.

Authors:  G D Yancopoulos; S Davis; N W Gale; J S Rudge; S J Wiegand; J Holash
Journal:  Nature       Date:  2000-09-14       Impact factor: 49.962

2.  Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas.

Authors:  W Philipp; L Speicher; C Humpel
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-08       Impact factor: 4.799

3.  Blood vessel maturation: vascular development comes of age.

Authors:  D C Darland; P A D'Amore
Journal:  J Clin Invest       Date:  1999-01       Impact factor: 14.808

Review 4.  Pericytes in the microvasculature.

Authors:  K K Hirschi; P A D'Amore
Journal:  Cardiovasc Res       Date:  1996-10       Impact factor: 10.787

5.  Fine structure of rat corneal vessels in advanced stages of wound healing.

Authors:  J Szalay; G D Pappas
Journal:  Invest Ophthalmol       Date:  1970-05

6.  Nomenclature of pericytes. Intramural and extramural.

Authors:  N Ashton; F de Oliveira
Journal:  Br J Ophthalmol       Date:  1966-03       Impact factor: 4.638

7.  Fine needle diathermy occlusion of corneal vessels.

Authors:  C T Pillai; H S Dua; P Hossain
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-07       Impact factor: 4.799

8.  Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor alpha, and transforming growth factor beta1 in human corneas with neovascularization.

Authors:  C Cursiefen; C Rummelt; M Küchle
Journal:  Cornea       Date:  2000-07       Impact factor: 2.651

9.  Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies.

Authors:  A Eberhard; S Kahlert; V Goede; B Hemmerlein; K H Plate; H G Augustin
Journal:  Cancer Res       Date:  2000-03-01       Impact factor: 12.701

10.  Lymphatic vessels in vascularized human corneas: immunohistochemical investigation using LYVE-1 and podoplanin.

Authors:  Claus Cursiefen; Ursula Schlötzer-Schrehardt; Michael Küchle; Lydia Sorokin; Silvana Breiteneder-Geleff; Kari Alitalo; David Jackson
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-07       Impact factor: 4.799

View more
  30 in total

1.  Three-year corneal graft survival rate in high-risk cases treated with subconjunctival and topical bevacizumab.

Authors:  Iva Dekaris; Nikica Gabrić; Nataša Drača; Maja Pauk-Gulić; Neven Miličić
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-11-16       Impact factor: 3.117

2.  [Late complications after chemical burns of the ocular surface. Surgical strategies for ocular surface reconstruction].

Authors:  B Bachmann; C Cursiefen
Journal:  Ophthalmologe       Date:  2011-10       Impact factor: 1.059

Review 3.  Emerging techniques to treat corneal neovascularisation.

Authors:  J Menzel-Severing
Journal:  Eye (Lond)       Date:  2011-10-07       Impact factor: 3.775

Review 4.  [Topical inhibition of angiogenesis at the cornea. Safety and efficacy].

Authors:  B Regenfuss; F Bock; B Bachmann; Y König; D Hos; A Parthasarathy; C Cursiefen
Journal:  Ophthalmologe       Date:  2009-05       Impact factor: 1.059

Review 5.  [Antiangiogenic therapy at the ocular surface: when, what and why?].

Authors:  F Bock; B Regenfuss; C Cursiefen
Journal:  Ophthalmologe       Date:  2011-03       Impact factor: 1.059

Review 6.  Clinical correlates of common corneal neovascular diseases: a literature review.

Authors:  Nizar Saleh Abdelfattah; Mohamed Amgad; Amira A Zayed; Hamdy Salem; Ahmed E Elkhanany; Heba Hussein; Nawal Abd El-Baky
Journal:  Int J Ophthalmol       Date:  2015-02-18       Impact factor: 1.779

7.  Safety and efficacy of the multitargeted receptor kinase inhibitor pazopanib in the treatment of corneal neovascularization.

Authors:  Francisco Amparo; Zahra Sadrai; Yiping Jin; Belen Alfonso-Bartolozzi; Haobing Wang; Hasanain Shikari; Joseph B Ciolino; James Chodosh; Ula Jurkunas; Debra A Schaumberg; Reza Dana
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-01-17       Impact factor: 4.799

8.  Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves the antiangiogenic efficacy for advanced stage mouse corneal neovascularization.

Authors:  Zhang Chaoran; Lin Zhirong; Xu Gezhi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-05-15       Impact factor: 3.117

9.  Computer simulation of glioma growth and morphology.

Authors:  Hermann B Frieboes; John S Lowengrub; S Wise; X Zheng; Paul Macklin; Elaine L Bearer; Vittorio Cristini
Journal:  Neuroimage       Date:  2007-03-23       Impact factor: 6.556

10.  Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis).

Authors:  Dimitri T Azar
Journal:  Trans Am Ophthalmol Soc       Date:  2006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.